Related Experiment Video
Updated: Jun 6, 2026
09:36
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
[Using metabolic cytoprotector Remaxol for urgently increased stability towards acute decompression syndrome]
Meditsina Truda I Promyshlennaia Ekologiia
|November 25, 2010
Summary
Remaxol, a metabolic cytoprotector, enhances stability against severe acute decompression syndrome. This medication reduces oxidant effects, lowers mortality, and increases survival time in animal models.
Area of Science:
- Biomedical research
- Pharmacology
- Toxicology
Background:
- Acute decompression syndrome (ADS) poses significant risks.
- Oxidative stress is a key factor in ADS.
- Effective cytoprotective agents are needed to mitigate ADS.
Purpose of the Study:
- To evaluate Remaxol's efficacy in preventing severe acute decompression syndrome.
- To assess Remaxol's impact on oxidant effects and survival rates.
Main Methods:
- Experiments conducted on 45 outbred male rabbits.
- Single intravenous injection of Remaxol administered.
- Evaluation of stability towards acute decompression and survival metrics.
Main Results:
- Remaxol injection significantly increased stability against ADS.
- The medication effectively relieved oxidant effects from decompression.
- Remaxol lowered mortality rates and increased animal survival time.
Conclusions:
- Remaxol demonstrates significant cytoprotective properties against severe ADS.
- The metabolic cytoprotector offers a promising therapeutic approach for decompression-related injuries.
More Related Videos
Related Concept Videos
01:30Acute Respiratory Failure-III
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:23Acute Respiratory Failure-IV
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
01:26Acute Coronary Syndrome V: Nursing Management
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...